Clot Composition & Thrombectomy Patents: Who Leads, Gaps 2026
Clot Composition and Thrombectomy Outcome Patents: Mapping a Concentrated Field
One filer dominates. The leading assignee alone accounts for 81 of 148 records in scope, with the top 5 combined reaching 86.5% of all records — this is a field with almost no open middle tier. Filings ran from 15 in 2017 to a peak of 36 in 2019, then settled into a steadier band; 2021's 11 rose to 2024's 12, a +9% gain over that span. 2025 and 2026 figures are still filling in as publications catch up to filing dates.
- 1LANG PHILIPP K81
- 2NEURAVI16
- 3KONINKLIJKE PHILIPS NV12
- 4ONPOINT MEDICAL INC10
- 5BIOSENSE WEBSTER (ISRAEL) LTD9
See the full clot composition and thrombectomy outcome analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
Who holds the most patents on clot composition and thrombectomy outcome?
One assignee holds 81 of the 148 records in this scope, making it by far the largest filer in the field. The next four ranked assignees combined bring the top 5 to 86.5% of all records, and the remaining ranked companies fill out the rest, with the tenth-placed assignee holding just 2 records. This is a field where a small number of players control almost all of the documented filing activity, so any competitive read should start with that leader’s specific claim scope rather than the market as a whole.
Is filing activity in clot composition and thrombectomy patents growing or slowing?
Filing peaked at 36 records in 2019 and has since settled to a lower, steadier level, with 11 filings in 2021 rising to 12 in 2024 — a +9% gain over that three-year span. The 2025 and 2026 figures in this data set are still incomplete because publication typically lags filing by around 18 months, so they should not be read as a decline. Based on the complete years, the field looks steady rather than either surging or contracting.
What patent classes cover clot composition and thrombectomy technology?
A61B, covering diagnosis and surgery, appears in 90.5% of all 148 records and is by far the dominant classification. A61F (implants and prostheses) follows at 33.8%, with image-processing (G06T), healthcare informatics (G16H) and body-fluid devices (A61M) each present in roughly 10% of records. Because a single record often carries several IPC codes, these percentages add up to more than 100% and should be read as independent measures of density, not shares of a whole.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Clot Composition and Thrombectomy Outcome covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.